Dallan Murray Sells 3,635 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insider Dallan Murray sold 3,635 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at $2,537,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sarepta Therapeutics Trading Up 0.7 %

Shares of SRPT stock opened at $136.04 on Wednesday. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $159.89. The company’s fifty day simple moving average is $125.47 and its two-hundred day simple moving average is $111.07. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The stock has a market capitalization of $12.86 billion, a price-to-earnings ratio of 1,236.73 and a beta of 0.95.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. During the same quarter in the prior year, the firm posted ($1.44) EPS. The firm’s quarterly revenue was up 63.1% on a year-over-year basis. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of analyst reports. UBS Group increased their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Evercore ISI upped their target price on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. Wedbush reiterated an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Royal Bank of Canada upped their price objective on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Finally, TheStreet upgraded Sarepta Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 4th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $160.60.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Principal Securities Inc. bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth $26,000. Mather Group LLC. purchased a new position in Sarepta Therapeutics during the first quarter worth about $28,000. Riggs Asset Managment Co. Inc. grew its position in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares in the last quarter. Montag A & Associates Inc. bought a new position in Sarepta Therapeutics in the 3rd quarter worth about $30,000. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.